Age 75 and older was an independent predictor of in-hospital adverse events in patients with tako-tsubo cardiomyopathy (HR 2.45; 95% CI 1.28-5.82; P=0.04).
Observational (n=190)
Yes
Effect estimate: HR 2.45 (95% CI 1.28-5.82)
p-value: p=0.04
Objectives To describe the clinical characteristics and in‐hospital outcomes of older adults with tako‐tsubo cardiomyopathy ( TTC ). Design Partially retrospective, partially prospective observational study. Setting Eleven Italian referral cardiac centers included in the Tako‐tsubo Italian Network. Participants One hundred ninety consecutive individuals with TTC (92.1% female, mean age 66) were divided into three groups according to age (<65, n = 78; 65–74, n = 61; ≥75, n = 51). Measurements Clinical findings and in‐hospital outcomes were evaluated in each group. Results Participants aged 65 and older had a greater prevalence of hypertension ( P = .001) and a lower glomerular filtration rate ( P < .001), and those aged 65 to 74 had a greater prevalence of psychiatric disorders ( P = .01), ST ‐segment elevation on admission ( P = .01) and a cerebrovascular disease ( P = .003) than those younger than 65. Despite similar left ventricular ejection fraction ( LVEF ) on admission ( P = .26), the oldest group had a lower LVEF at discharge ( P = .03). Inotropic agents were used more frequently in older adults ( P = .03). In‐hospital composite adverse events (all‐cause death, acute heart failure, life‐threatening arrhythmias, stroke, and cardiogenic shock; P = .03) and overall complications ( P = .004) were more common in participants aged 75 and older. Overall in‐hospital mortality was low (2.8%) but was more prevalent in participants aged 75 and older (6.3%). On multivariate analysis, age of 75 and older (hazard ratio ( HR ) = 2.45, 95% confidence interval ( CI ) = 1.28–5.82, P = .04) and LVEF on admission ( HR = 0.874, 95% CI = 0.81–0.95, P < .001) were the only independent predictors of in‐hospital adverse events. Conclusion The clinical profile of participants aged 75 and older with TTC was different from that of those younger than 75 with TTC , and they had a higher in‐hospital complication rate.
Citro et al. (Mon,) conducted a observational in Tako-tsubo cardiomyopathy (n=190). Age ≥75 years vs. Age <75 years was evaluated on In-hospital composite adverse events (all-cause death, acute heart failure, life-threatening arrhythmias, stroke, and cardiogenic shock) (HR 2.45, 95% CI 1.28-5.82, p=0.04). Age 75 and older was an independent predictor of in-hospital adverse events in patients with tako-tsubo cardiomyopathy (HR 2.45; 95% CI 1.28-5.82; P=0.04).